In the announcement, FDA Commissioner Mackary said, “Bayesian methodologies help address two of the biggest problems of drug ...
In today's ACT Brief, we explore the leadership priorities that enable meaningful AI gains in clinical research, how Bayesian ...
Rare disease is a major – and growing – area of clinical research and drug development. Of the FDA’s 46 novel drug approvals in 2025, more than half (26) were designated as rare disease (orphan) ...
The common antidepressant fluvoxamine significantly reduces fatigue and improves quality of life for patients suffering from ...
A burgeoning field is launching its first clinical trial to find out whether dialling back cell development can safely ...
In an effort to increase access to evidence-based interventions to help manage anxiety and depression, Mass General Brigham ...
Biomedical data analysis has evolved rapidly from convolutional neural network-based systems toward transformer architectures and large-scale foundation ...
April is the awareness month for esophageal, head and neck and testicular cancers. To speak to our experts, reach out to media@fredhutch.org.
Despite substantial progress in cancer treatment, durable benefit is still frequently limited by the ability of tumors to adapt under therapeutic pressure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results